Latest Conference

Check out these brief summaries on cognitive impairment in schizophrenia from an excellent session at the ACNP 2023 Annual Meeting!

DBS in psychiatry: What challenges stand between this treatment and success? Alik Widge, MD, PhD, shares more at the ACNP 2023 Annual meeting.

Did you catch the President's Plenary at the ACNP 2023 Annual Meeting?

Navacaprant—a novel, oral, once-daily, highly selective kappa opioid receptor antagonist that is currently in phase 3 development as a monotherapy for major depressive disorder.

Don't miss this ACNP 2023 Annual Meeting session!

Michael F. Myers, MD provided tips and advice to clinicians who might be dealing with a patient contemplating suicide.

“Epidemiological surveys have shown that gender gaps and alcohol consumption and alcohol-related harms are narrowing for women and men—such that alcohol is growing women’s health issue.”

Tony Thrasher, DO, DFAPA, shared his thoughts on emergency psychiatry: an honor and a great stressor.

What are some key considerations in diagnosing bipolar disorder? Joseph F. Goldberg, MD, shares insights at the recent 2023 Annual Psychiatric Times World CME Conference.

What are the treatment options for insomnia when avoiding benzodiazepines? John W. Winkelman MD, PhD, shares insights and guidance at the 2023 Annual Psychiatric Times World CME Conference.

Here’s why you should initiate clozapine sooner in patients with treatment-resistant schizophrenia.

An expert discusses motivational interviewing at the 2023 Annual Psychiatric Times™ World CME Conference.

Sanjai Rao, MD, shared best practices for utilizing long-acting injectable antipsychotics at the 2023 Psychiatric Times World CME Conference.

Don't miss the the 2023 Psychiatric Times World CME conference, where our Editor in Chief will present on the 14 different types of dementia!

The newest class of medications to treat insomnia have many advantages.

Don't miss updates on schizophrenia at our conference, beginning at 3:10PM EST!

Our Editor in Chief explains why you should attend our conference!

An expert discusses the connections between the 2 highly comorbid diseases and some ways to effectively treat both diseases simultaneously.

New positive data for novel ADHD treatment.

An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.

Have you registered for the 2023 Annual Psychiatric Times World CME Conference?

Christoph Correll, MD, shares more on paliperidone palmitate 6-month for the treatment of schizophrenia.

Investigators noted sustained improvement in depressive symptoms for up to 6.5 years.

The relationship of this key symptom of major depressive disorder and patient burden is not well understood. These two posters covered it.

“Among employed adults with TRD, esketamine nasal spray treatment was associated with significantly larger improvements in WPL and related costs compared to quetiapine extended-release treatment.”

These 3 posters covered the efficacy and safety of paliperidone palmitate in patients with schizophrenia.

A psychiatry resident from Mexico reflects on the field.

Introspections from an international resident following a US conference shed light on issues in geriatric psychiatry and more.